Anti-Angiogenic Therapy: Albumin-Binding Proteins Could Mediate Mechanisms Underlying the Accumulation of Small Molecule Receptor Tyrosine Kinase Inhibitors in Normal Tissues with Potential Harmful Effects on Health

Overview

Journal Diseases

Date 2021 Apr 30

PMID 33920299

Citations 3

Authors

Nicolae Ghinea

Affiliations

Soon will be listed here.

Abstract

Anti-angiogenics currently used in cancer therapy target angiogenesis by two major mechanisms: (i) neutralizing angiogenic factors or their receptors by using macromolecule anti-angiogenic drugs (e.g., therapeutic antibodies), and (ii) blocking intracellularly the activity of receptor tyrosine kinases with small molecule (M < 1 kDa) inhibitors. Anti-angiogenics halt the growth and spread of cancer, and significantly prolong the disease-free survival of the patients. However, resistance to treatment, insufficient efficacy, and toxicity limit the success of this antivascular therapy. Published evidence suggests that four albumin-binding proteins (ABPs) (gp18, gp30, gp60/albondin, and secreted protein acidic and cysteine-rich (SPARC)) could be responsible for the accumulation of small molecule receptor tyrosine kinase inhibitors (RTKIs) in normal organs and tissues and therefore responsible for the side effects and toxicity associated with this type of cancer therapy. Drawing attention to these studies, this review discusses the possible negative role of albumin as a drug carrier and the rationale for a new strategy for cancer therapy based on follicle-stimulating hormone receptor (FSHR) expressed on the luminal endothelial cell surface of peritumoral blood vessels associated with the major human cancers. This review should be relevant to the audience and the field of cancer therapeutics and angiogenesis/microvascular modulation-based interventions.

Citing Articles

Counterion Tuning of Near-Infrared Organic Salts Dictates Phototoxicity to Inhibit Tumor Growth.

Broadwater D, Medeiros H, Bates M, Roshanzadeh A, Teoh S, P Ogrodzinski M ACS Appl Mater Interfaces. 2022; 14(48):53511-53522.

PMID: 36408853 PMC: 9743086. DOI: 10.1021/acsami.2c16252.

Why 90% of clinical drug development fails and how to improve it?.

Sun D, Gao W, Hu H, Zhou S Acta Pharm Sin B. 2022; 12(7):3049-3062.

PMID: 35865092 PMC: 9293739. DOI: 10.1016/j.apsb.2022.02.002.

Structure‒tissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety.

Gao W, Hu H, Dai L, He M, Yuan H, Zhang H Acta Pharm Sin B. 2022; 12(5):2462-2478.

PMID: 35646532 PMC: 9136610. DOI: 10.1016/j.apsb.2022.02.015.

References

Kuczynski E, Vermeulen P, Pezzella F, Kerbel R, Reynolds A . Vessel co-option in cancer. Nat Rev Clin Oncol. 2019; 16(8):469-493. DOI: 10.1038/s41571-019-0181-9. View

Boehm T, Folkman J, Browder T, OReilly M . Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997; 390(6658):404-7. DOI: 10.1038/37126. View

Folkman J . Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 1972; 175(3):409-16. PMC: 1355186. DOI: 10.1097/00000658-197203000-00014. View

Clementi F, Palade G . Intestinal capillaries. I. Permeability to peroxidase and ferritin. J Cell Biol. 1969; 41(1):33-58. PMC: 2107738. DOI: 10.1083/jcb.41.1.33. View

Dobbin S, Cameron A, Petrie M, Jones R, Touyz R, Lang N . Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart. 2018; 104(24):1995-2002. PMC: 6268130. DOI: 10.1136/heartjnl-2018-313726. View

Jussing E, Lu L, Grafstrom J, Tegnebratt T, Arnberg F, Rosik H . [Ga]ABY-028: an albumin-binding domain (ABD) protein-based imaging tracer for positron emission tomography (PET) studies of altered vascular permeability and predictions of albumin-drug conjugate transport. EJNMMI Res. 2020; 10(1):106. PMC: 7509035. DOI: 10.1186/s13550-020-00694-2. View

Semeniuk-Wojtas A, Lubas A, Stec R, Szczylik C, Niemczyk S . Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients. Int J Mol Sci. 2016; 17(12). PMC: 5187873. DOI: 10.3390/ijms17122073. View

Yang W, Green K, Briones A, Burton D, Barbas 3rd C . CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol. 1995; 254(3):392-403. DOI: 10.1006/jmbi.1995.0626. View

Ebos J, Lee C, Cruz-Munoz W, Bjarnason G, Christensen J, Kerbel R . Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15(3):232-9. PMC: 4540346. DOI: 10.1016/j.ccr.2009.01.021. View

10.

Kuczynski E, Reynolds A . Vessel co-option and resistance to anti-angiogenic therapy. Angiogenesis. 2019; 23(1):55-74. DOI: 10.1007/s10456-019-09698-6. View

11.

Randrup Hansen C, Grimm D, Bauer J, Wehland M, Magnusson N . Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma. Int J Mol Sci. 2017; 18(2). PMC: 5343994. DOI: 10.3390/ijms18020461. View

12.

Ghinea N, Hasu M . Charge effect on binding, uptake and transport of ferritin through fenestrated endothelium. J Submicrosc Cytol. 1986; 18(4):647-59. View

13.

Ellis L, Hicklin D . VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8(8):579-91. DOI: 10.1038/nrc2403. View

14.

Hashizume H, Baluk P, Morikawa S, McLean J, Thurston G, Roberge S . Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000; 156(4):1363-80. PMC: 1876882. DOI: 10.1016/S0002-9440(10)65006-7. View

15.

Vermeulen P, Verhoeven D, Hubens G, Marck E, Goovaerts G, Huyghe M . Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas. Ann Oncol. 1995; 6(1):59-64. DOI: 10.1093/oxfordjournals.annonc.a059043. View

16.

Larson S, Carrasquillo J, Reynolds J . Radioimmunodetection and radioimmunotherapy. Cancer Invest. 1984; 2(5):363-81. DOI: 10.3109/07357908409040313. View

17.

Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A . Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med. 2010; 363(17):1621-30. DOI: 10.1056/NEJMoa1001283. View

18.

Baldewijns M, Thijssen V, Van den Eynden G, Van Laere S, Bluekens A, Roskams T . High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile. Br J Cancer. 2007; 96(12):1888-95. PMC: 2359956. DOI: 10.1038/sj.bjc.6603796. View

19.

Montemagno C, Pages G . Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs. Front Cell Dev Biol. 2020; 8:584. PMC: 7381352. DOI: 10.3389/fcell.2020.00584. View

20.

Ghinea N, Eskenasy M, Simionescu M, Simionescu N . Endothelial albumin binding proteins are membrane-associated components exposed on the cell surface. J Biol Chem. 1989; 264(9):4755-8. View